


**WHAT IS CLAIMED IS**

1. A method of inhibiting human stearoyl-CoA desaturase (hSCD) activity comprising contacting a source of hSCD with a compound of formula (I):



wherein:

x and y are each independently 1, 2 or 3;

W is -O-, -N(R<sup>1</sup>)-, -C(R<sup>1</sup>)<sub>2</sub>-, -C(O)-, -OC(O)-, -S(O)<sub>t</sub>-; (where t is 0, 1 or 2), -N(R<sup>1</sup>)S(O)<sub>t</sub>- (where t is 1 or 2), -S(O)<sub>2</sub>N(R<sup>1</sup>)-, -C(O)N(R<sup>1</sup>)-, -C(S)N(R<sup>1</sup>)-, -OS(O)<sub>2</sub>N(R<sup>1</sup>)-, -OC(O)N(R<sup>1</sup>)-, -OC(S)N(R<sup>1</sup>)-, -N(R<sup>1</sup>)C(O)N(R<sup>1</sup>)- or -N(R<sup>1</sup>)C(S)N(R<sup>1</sup>)-;

V is  $-C(O)-$ ,  $-C(S)-$ ,  $-C(O)N(R^1)-$ ,  $-C(O)O-$ ,  $-C(S)O-$ ,  $-S(O)_t-$  (where t is 1 or 2),  $-S(O)_tN(R^1)-$  (where t is 1 or 2) or  $-C(R^{11})H$ ;

each R<sup>1</sup> is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aryl

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl, and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other:

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other:

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^7$  and  $R^{7a}$  together, or  $R^8$  and  $R^{8a}$  together, or  $R^9$  and  $R^{9a}$  together, or  $R^{10}$  and  $R^{10a}$  together are an oxo group, provided that when  $V$  is  $-C(O)-$ ,  $R^7$  and  $R^{7a}$  together or  $R^8$  and  $R^{8a}$  together do not form an oxo group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;


or one of  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ , and  $R^{7a}$  together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ , and  $R^{9a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

$R^{11}$  is hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

2. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I):



wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$W$  is  $-O-$ ,  $-N(R^1)-$ ,  $-C(R^1)_2-$ ,  $-C(O)-$ ,  $-OC(O)-$ ,  $-S(O)_t-$ ; (where  $t$  is 0, 1 or 2),  $-N(R^1)S(O)_t-$  (where  $t$  is 1 or 2),  $-S(O)_2N(R^1)-$ ,  $-C(O)N(R^1)-$ ,  $-C(S)N(R^1)-$ ,  $-OS(O)_2N(R^1)-$ ,  $-OC(O)N(R^1)-$ ,  $-OC(S)N(R^1)-$ ,  $-N(R^1)C(O)N(R^1)-$  or  $-N(R^1)C(S)N(R^1)-$ ;

$V$  is  $-C(O)-$ ,  $-C(S)-$ ,  $-C(O)N(R^1)-$ ,  $-C(S)N(R^1)-$ ,  $-C(O)O-$ ,  $-C(S)O-$ ,

$-S(O)_t-$  (where  $t$  is 1 or 2),  $-S(O)_tN(R^1)-$  (where  $t$  is 1 or 2) or  $-C(R^{11})H$ ;

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclalkyl,  $C_1$ - $C_{12}$ heteroaryl, and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^3$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^7$  and  $R^{7a}$  together, or  $R^8$  and  $R^{8a}$  together, or  $R^9$  and  $R^{9a}$  together, or  $R^{10}$  and  $R^{10a}$  together are an oxo group, provided that when  $V$  is  $-C(O)-$ ,  $R^7$  and  $R^{7a}$  together or  $R^8$  and  $R^{8a}$  together do not form an oxo group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or one of  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ , and  $R^{7a}$  together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ , and  $R^{9a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

$R^{11}$  is hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl;


a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

3. The method of Claim 2 wherein the mammal is a human.

4. The method of Claim 3 wherein the disease or condition is selected from the group consisting of Type II diabetes, fatty liver, non-alcoholic steatohepatitis,

impaired glucose tolerance, insulin resistance, obesity, dyslipidemia and metabolic syndrome and any combination of these.

5. The method of Claim 4 wherein the disease or condition is Type II diabetes.
6. The method of Claim 4 wherein the disease or condition is obesity.
7. The method of Claim 4 wherein the disease or condition is metabolic syndrome.
8. The method of Claim 4 wherein the disease or condition is fatty liver.
9. The method of Claim 4 wherein the disease or condition is non-alcoholic steatohepatitis.
10. A compound of formula (IIa):



wherein:

x and y are each independently 1, 2 or 3;

R<sup>1</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>7</sub>-C<sub>12</sub>alkyl, C<sub>3</sub>-C<sub>12</sub>alkenyl, C<sub>7</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>13</sub>-C<sub>19</sub>aralkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>3</sub>-C<sub>12</sub>heterocycl, and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl, provided that R<sup>2</sup> is not pyrazinyl, pyridinyl, pyrrolidinyl or imidazolyl;

or R<sup>2</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocycl, aryl and

heteroaryl, where some or all of the rings may be fused to each other;

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ alkenyl,  $C_3$ - $C_{12}$ hydroxyalkyl,  $C_3$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$  heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$  and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^9$  and  $R^{9a}$  together, or  $R^{10}$  and  $R^{10a}$  together form an oxo group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or one of  $R^7$ ,  $R^{7a}$ ,  $R^{10}$  and  $R^{10a}$ , together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$ , form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

11. The compound of Claim 10 wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$R^1$  is selected from the group consisting of hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_7$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ alkenyl,  $C_7$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl,  $C_{13}$ - $C_{19}$ aralkyl,  $C_1$ - $C_{12}$ heteroaryl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_3$ - $C_{12}$ heterocyclyl and  $C_3$ - $C_{12}$ heteroarylalkyl, provided that  $R^2$  is not pyrazinyl, pyridinonyl, pyrrolidinonyl or imidazolyl;

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ alkenyl,  $C_3$ - $C_{12}$ hydroxyalkyl,  $C_3$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$  heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$  and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl.

12. The compound of Claim 11 wherein:

$x$  and  $y$  are each 1;

$R^1$  is selected from the group consisting of hydrogen or  $C_1$ - $C_{12}$ alkyl;

$R^2$  is selected from the group consisting of  $C_7$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ alkenyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl,  $C_{13}$ - $C_{19}$ aralkyl,  $C_1$ - $C_{12}$ heteroaryl,  $C_3$ - $C_{12}$ heterocyclylalkyl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$  heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$  and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl.

13. The compound of Claim 12 wherein:

$R^2$  is  $C_3$ - $C_{12}$ cycloalkyl or  $C_4$ - $C_{12}$ cycloalkylalkyl;

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ cycloalkyl or  $C_4$ - $C_{12}$ cycloalkylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each hydrogen; and

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$  and  $R^{10a}$  are each hydrogen or  $C_1$ - $C_3$ alkyl.

14. The compound of Claim 13 wherein:

$R^2$  is  $C_3$ - $C_{12}$ cycloalkyl; and


$R^3$  is  $C_3$ - $C_{12}$ cycloalkyl.

15. The compound of Claim 14, namely, Cyclohexanecarboxylic acid [6-(4-cyclohexanecarbonyl-piperazin-1-yl)pyridin-3-yl]amide.

16. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 10.

17. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 10.

18. A compound of formula (IIb):



wherein:

x and y are each independently 1, 2 or 3;

R<sup>1</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or R<sup>2</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>, cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl, provided that R<sup>3</sup> is not phenyl substituted with optionally substituted thienyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>13</sup>)<sub>2</sub>;

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup>, and R<sup>10a</sup> are each independently selected

from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

or R<sup>9</sup> and R<sup>9a</sup> together, or R<sup>10</sup> and R<sup>10a</sup> together form an oxo group, while the remaining R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup>, and R<sup>10a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

or one of R<sup>7</sup>, R<sup>7a</sup>, R<sup>10</sup> and R<sup>10a</sup>, together with one of R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup> and R<sup>9a</sup>, form an alkylene bridge, while the remaining R<sup>10</sup>, R<sup>10a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, and R<sup>9a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl; and

each R<sup>13</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

19. The compound of Claim 18 wherein:

x and y are each independently 1, 2 or 3;

R<sup>1</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>, cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl, provided that R<sup>3</sup> is not phenyl substituted with optionally substituted thienyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>13</sup>)<sub>2</sub>;

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup>, and R<sup>10a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl, or

R<sup>10</sup> and R<sup>10a</sup> together form an oxo group and the remaining R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup> and R<sup>9a</sup> are each hydrogen;

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl; and

each R<sup>13</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.

20. The compound of Claim 19 wherein:

x and y are each 1;

R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>12</sub>alkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>, cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl, provided that R<sup>3</sup> is not phenyl substituted with optionally substituted thienyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each hydrogen;

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup> and R<sup>10a</sup> are each hydrogen; or

R<sup>10</sup> and R<sup>10a</sup> together form an oxo group and the remaining R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup> and R<sup>9a</sup> are each hydrogen; and

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl.

21. The compound of Claim 20 wherein:

R<sup>2</sup> is C<sub>1</sub>-C<sub>12</sub>alkyl; and

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy.

22. The compound of Claim 21 selected from the group consisting of the following:

4-Methylpentanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;

Hexanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;

Heptanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;

Heptanoic acid {6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl}amide; and

Hexanoic acid {6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl}amide.

23. The compound of Claim 20 wherein:

$R^2$  is  $C_3$ - $C_{12}$ cycloalkyl; and

$R^3$  is phenyl optionally substituted by one or more substituents selected from halo,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl and  $C_1$ - $C_6$ trihaloalkoxy.

24. The compound of Claim 23, namely, Cyclohexanecarboxylic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide.

25. The compound of Claim 20 wherein:

$R^2$  is  $C_7$ - $C_{12}$ aralkyl optionally substituted by one or more substituents selected from halo,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl and  $C_1$ - $C_6$ trihaloalkoxy; and

$R^3$  is phenyl optionally substituted by one or more substituents selected from halo,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl and  $C_1$ - $C_6$ trihaloalkoxy.


26. The compound of Claim 25 selected from the group consisting of the following:

3-Phenyl- $N$ -(6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl)propionamide; 4-Phenyl- $N$ -(6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl)butyramide; and  $N$ -(6-[2-Oxo-4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl)-4-phenylbutyramide.

27. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 18.

28. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 18.

29. The compound of formula (III):



wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$V_a$  is  $-C(O)-$ ,  $-C(S)-$ ,  $-C(O)N(R^1)-$ ,  $-C(S)N(R^1)-$ ,  $-C(O)O-$ ,  $-C(S)O-$ ,  $-S(O)_t$ - (where  $t$  is 1 or 2) or  $-S(O)_tN(R^1)-$  (where  $t$  is 1 or 2);

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_1$ - $C_6$ alkoxy,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

$R^3$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^7$  and  $R^{7a}$  together, or  $R^8$  and  $R^{8a}$  together, or  $R^9$  and  $R^{9a}$  together, or  $R^{10}$  and  $R^{10a}$  together are an oxo group, provided that when  $V_a$  is  $-C(O)-$ ,  $R^7$  and  $R^{7a}$  together or  $R^8$  and  $R^{8a}$  together do not form an oxo group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or one of  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ , and  $R^{7a}$  together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ , and  $R^{9a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and  
 each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl;  
 a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

30. The compound of Claim 29 wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$V_a$  is  $-C(O)-$  or  $-C(S)-$ ;

$R^1$  is selected from the group consisting of hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_1$ - $C_6$ alkoxy,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl.

31. The compound of Claim 30 wherein:

$x$  and  $y$  are each 1;

$V_a$  is  $-C(O)-$ ;

$R^1$  is hydrogen or  $C_1$ - $C_{12}$ alkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_1$ - $C_6$ alkoxy,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is naphthyl or phenyl, each optionally substituted by one or more

substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>, cycloalkyl, heterocyclyl, heteroaryl and heteroaryl(cycloalkyl);

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each hydrogen;

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup>, and R<sup>10a</sup> are each hydrogen; and each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl.

32. The compound of Claim 31 wherein:

R<sup>2</sup> is C<sub>1</sub>-C<sub>12</sub>alkyl or C<sub>7</sub>-C<sub>12</sub>aralkyl optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy;

R<sup>3</sup> is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy.

33. The compound of Claim 32 selected from the group consisting of the following:

Pentane-1-sulfonic acid {6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl}amide;

Butane-1-sulfonic acid {6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl}amide;

Hexane-1-sulfonic acid {6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl}amide;

Pentane-1-sulfonic acid {6-[4-(2-bromobenzoyl)piperazin-1-yl]pyridin-3-yl}amide;

Hexane-1-sulfonic acid {6-[4-(2,5-dichlorobenzoyl)-piperazin-1-yl]pyridin-3-yl}amide;

Pentane-1-sulfonic acid {6-[4-(2,5-dichlorobenzoyl)-piperazin-1-yl]pyridin-3-yl}amide;

Hexane-1-sulfonic acid {6-[4-(naphthalene-1-carbonyl)-piperazin-1-yl]pyridin-3-yl}amide;

Pentane-1-sulfonic acid {6-[4-(naphthalene-1-carbonyl)-piperazin-1-yl]pyridin-3-yl}amide; and

3-Phenylpropane-1-sulfonic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide.

34. The compound of Claim 31 wherein:


R<sup>2</sup> is C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl or C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy.

35. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 29.

36. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 29.

37. The compound of formula (IV):



wherein:

x and y are each independently 1, 2 or 3;

V<sub>a</sub> is -C(O)-, -C(S)-, -C(O)N(R<sup>1</sup>)-, -C(S)N(R<sup>1</sup>)-, -C(O)O-, -C(S)O-, -S(O)<sub>t</sub>-(where t is 1 or 2) or -S(O)<sub>t</sub>N(R<sup>1</sup>)- (where t is 1 or 2);

each R<sup>1</sup> is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or R<sup>2</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are

independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

$R^3$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^7$  and  $R^{7a}$  together, or  $R^8$  and  $R^{8a}$  together, or  $R^9$  and  $R^{9a}$  together, or  $R^{10}$  and  $R^{10a}$  together are an oxo group, provided that when  $V_a$  is  $-C(O)-$ ,  $R^7$  and  $R^{7a}$  together or  $R^8$  and  $R^{8a}$  together do not form an oxo group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or one of  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ , and  $R^{7a}$  together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ , and  $R^{9a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

38. The compound of Claim 37 wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$V_a$  is  $-C(O)-$ ,  $-C(S)-$ ,  $-C(O)N(R^1)-$ ,  $-C(S)N(R^1)-$ ,  $-C(O)O-$ ,  $-S(O)_t-$  (where  $t$  is 1 or 2) or  $-S(O)_tN(R^1)-$  (where  $t$  is 1 or 2);

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl.

39. The compound of Claim 38 wherein:

$x$  and  $y$  are each 1;

$V_a$  is  $-C(O)-$ ;

each  $R^1$  is independently hydrogen or  $C_1$ - $C_6$ alkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ alkenyl,  $C_3$ - $C_{12}$ hydroxyalkyl,  $C_3$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$  heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each hydrogen;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each hydrogen; and

each  $R^{12}$  is independently selected from hydrogen,  $C_1$ - $C_6$ alkyl,  $C_3$ - $C_6$ cycloalkyl, aryl or aralkyl.

40. The compound of Claim 39 wherein:

$R^2$  is  $C_1$ - $C_{12}$ alkyl or  $C_7$ - $C_{12}$ aralkyl optionally substituted by one or more substituents selected from the group consisting of halo,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl and  $C_1$ - $C_6$ trihaloalkoxy; and

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ cycloalkyl, aryl,  $C_3$ - $C_{12}$ heterocyclyl or  $C_1$ - $C_{12}$  heteroaryl.

41. The compound of Claim 40 wherein  $R^3$  is  $C_3$ - $C_{12}$ cycloalkyl.

42. The compound of Claim 41 selected from the group consisting of the following:

1-[6-(4-Cyclohexanecarbonylpiperazin-1-yl)pyridin-3-yl]-3-pentylurea; and  
1-[6-(4-Cyclopentanecarbonylpiperazin-1-yl)pyridin-3-yl]-3-pentylurea.

43. The compound of Claim 40 wherein R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy.

44. The compound of Claim 43 selected from the group consisting of the following:

1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea;  
1-Butyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea;  
1-Phenethyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}urea;  
1-Benzyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; and  
1-(4-Fluorobenzyl)-3-{6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl}urea.

45. The compound of Claim 40 wherein R<sup>3</sup> is piperidinyl optionally substituted by C<sub>1</sub>-C<sub>6</sub>alkyl or C<sub>7</sub>-C<sub>12</sub>aralkyl, wherein the C<sub>7</sub>-C<sub>12</sub>aralkyl group is optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy.

46. The compound of Claim 45, namely, 1-{6-[4-(1-Benzylpiperidine-4-carbonyl)piperazin-1-yl]-pyridin-3-yl}-3-pentylurea.

47. The compound of Claim 40 wherein R<sup>3</sup> is pyridinyl optionally substituted by one or more substituents selected from the group consisting of halo or C<sub>1</sub>-C<sub>6</sub>alkyl.

48. The compound of Claim 47 selected from the group consisting of the following:


1-Pentyl-3-{6-[4-(pyridine-2-carbonyl)piperazin-1-yl]-pyridin-3-yl}urea; and  
1-Pentyl-3-{6-[4-(pyridine-4-carbonyl)piperazin-1-yl]-pyridin-3-yl}urea.

49. A method of treating a disease or condition mediated by stearoyl-CoA

desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 37.

50. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 37.

51. The compound of formula (V):



wherein:

x and y are each independently 1, 2 or 3;

W<sub>a</sub> is -O-, -N(R<sup>1</sup>)- or -S(O)<sub>t</sub>- (where t is 0, 1 or 2);

V<sub>a</sub> is -C(O)-, -C(S)-, -C(O)N(R<sup>1</sup>)-, -C(S)N(R<sup>1</sup>)-, -C(O)O-, -C(S)O-, -S(O)<sub>t</sub>- (where t is 1 or 2) or -S(O)<sub>t</sub>N(R<sup>1</sup>)- (where t is 1 or 2);

each R<sup>1</sup> is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or R<sup>2</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or R<sup>3</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are

independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^7$  and  $R^{7a}$  together, or  $R^8$  and  $R^{8a}$  together, or  $R^9$  and  $R^{9a}$  together, or  $R^{10}$  and  $R^{10a}$  together are an oxo group, provided that when  $V_a$  is  $-C(O)-$ ,  $R^7$  and  $R^{7a}$  together or  $R^8$  and  $R^{8a}$  together do not form an oxo group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or one of  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ , and  $R^{7a}$  together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ , and  $R^{9a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

52. The compound of Claim 51 wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$W_a$  is  $-O-$ ,  $-N(R^1)-$  or  $-S(O)_t-$  (where  $t$  is 0, 1 or 2);

$V_a$  is  $-C(O)-$ ,  $-C(S)-$ ,  $-C(O)N(R^1)-$ ,  $-C(S)N(R^1)-$ ,  $-C(O)O-$ ,  $-S(O)_t-$  (where  $t$  is 1 or 2) or  $-S(O)_tN(R^1)-$  (where  $t$  is 1 or 2);

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and  
 each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl.

53. The compound of Claim 52 wherein:

$x$  and  $y$  are each 1;

$W_a$  is  $-O$ ;

$V_a$  is  $-C(O)-$  or  $-C(S)-$ ;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ alkenyl,  $C_3$ - $C_{12}$ hydroxyalkyl,  $C_3$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxy,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$  heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each hydrogen; and

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each hydrogen.

54. The compound of Claim 53 wherein:

$V_a$  is  $-C(O)-$ ;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl; and

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$  heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl.

55. The compound of Claim 52 wherein:

$x$  and  $y$  are each 1;

$W_a$  is  $-N(R^1)-$ ;

$V_a$  is  $-C(O)-$  or  $-C(S)-$ ;

$R^1$  is hydrogen or  $C_1$ - $C_6$ alkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,

C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is selected from the group consisting of C<sub>3</sub>-C<sub>12</sub>alkyl, C<sub>3</sub>-C<sub>12</sub>alkenyl, C<sub>3</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>3</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>alkoxy, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub> heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each hydrogen; and

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup>, and R<sup>10a</sup> are each hydrogen.

56. The compound of Claim 55 wherein:

V<sub>a</sub> is -C(O)-;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl; and

R<sup>3</sup> is selected from the group consisting of C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub> heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl.

57. The compound of Claim 52 wherein:

x and y are each 1;

W<sub>a</sub> is -S(O)<sub>t</sub>- (where t is 0, 1 or 2);

V<sub>a</sub> is -C(O)- or -C(S)-;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is selected from the group consisting of C<sub>3</sub>-C<sub>12</sub>alkyl, C<sub>3</sub>-C<sub>12</sub>alkenyl, C<sub>3</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>3</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>alkoxy, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub> heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each hydrogen; and

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup>, and R<sup>10a</sup> are each hydrogen.

58. The compound of Claim 57 wherein:

V<sub>a</sub> is -C(O)-;


$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl; and

$R^3$  is selected from the group consisting of  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$  heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl.

59. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 51.

60. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 51.

61. A compound of formula (Ia):



wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$W$  is  $-N(R^1)S(O)_t-$  (where  $t$  is 1 or 2);

$V$  is  $-C(O)-$ ,  $-C(S)-$ ,  $-C(O)N(R^1)-$ ,  $-C(S)N(R^1)-$ ,  $-C(O)O-$ ,  $-C(S)O-$ ,  $-S(O)_t-$  (where  $t$  is 1 or 2),  $-S(O)_tN(R^1)-$  (where  $t$  is 1 or 2) or  $-C(R^{11})H$ ;

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl, and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are

independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^3$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^7$  and  $R^{7a}$  together, or  $R^8$  and  $R^{8a}$  together, or  $R^9$  and  $R^{9a}$  together, or  $R^{10}$  and  $R^{10a}$  together are an oxo group, provided that when  $V$  is  $-C(O)-$ ,  $R^7$  and  $R^{7a}$  together or  $R^8$  and  $R^{8a}$  together do not form an oxo group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or one of  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ , and  $R^{7a}$  together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ , and  $R^{9a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

$R^{11}$  is hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

62. The compound of Claim 61 wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$V$  is  $-C(O)-$  or  $-C(S)-$ ;

$R^1$  is hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl, and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_1$ - $C_{12}$ alkoxy,  $C_2$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl.

63. The compound of Claim 62 wherein:

$x$  and  $y$  are each 1;

$V$  is  $-C(O)-$ ;

$R^1$  is hydrogen,  $C_1$ - $C_{12}$ alkyl or  $C_4$ - $C_{12}$ cycloalkylalkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclylalkyl and  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is aryl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl,  $C_1$ - $C_6$ trihaloalkoxy,  $C_1$ - $C_6$ alkylsulfonyl,  $-N(R^{12})_2$ ,  $-OC(O)R^{12}$ ,  $-C(O)OR^{12}$ ,  $-S(O)_2N(R^{12})_2$ , cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1$ - $C_6$ alkyl.

64. The compound of Claim 63 wherein:

$x$  and  $y$  are each 1;

$V$  is  $-C(O)-$ ;

$R^1$  is hydrogen,  $C_1$ - $C_{12}$ alkyl or  $C_4$ - $C_{12}$ cycloalkylalkyl;

$R^2$  is  $C_1$ - $C_{12}$ alkyl or  $C_2$ - $C_{12}$ alkenyl;

$R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl,  $C_1$ - $C_6$ trihaloalkoxy,  $C_1$ - $C_6$ alkylsulfonyl,  $-N(R^{12})_2$ ,  $-OC(O)R^{12}$ ,  $-C(O)OR^{12}$  and

-S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, bromo, fluoro or chloro; and

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup> and R<sup>10a</sup> are each hydrogen.

65. The compound of Claim 63 wherein:

x and y are each 1;

V is -C(O)-;

R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl or C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl;

R<sup>2</sup> is C<sub>3</sub>-C<sub>12</sub>cycloalkyl or C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup> and -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, bromo, fluoro or chloro; and

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup> and R<sup>10a</sup> are each hydrogen.

66. The compound of Claim 65 wherein:

R<sup>2</sup> is C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy;

R<sup>4</sup> and R<sup>6</sup> are both hydrogen; and

R<sup>5</sup> is hydrogen or bromo.

67. The compound of Claim 66 selected from the group consisting of the following:

5-Bromo-6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridine-3-sulfonic acid (2-cyclopropylethyl)amide; and

6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]pyridine-3-sulfonic acid (2-cyclopropylethyl)amide.

68. The compound of Claim 63 wherein:

x and y are each 1;

V is -C(O)-;

$R^1$  is hydrogen,  $C_1$ - $C_{12}$ alkyl or  $C_4$ - $C_{12}$ cycloalkylalkyl;

$R^2$  is  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$ heterocyclalkyl or  $C_3$ - $C_{12}$ heteroarylalkyl;

$R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl,  $C_1$ - $C_6$ trihaloalkoxy,  $C_1$ - $C_6$ alkylsulfonyl,  $-N(R^{12})_2$ ,  $-OC(O)R^{12}$ ,  $-C(O)OR^{12}$  and  $-S(O)_2N(R^{12})_2$ ;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro or chloro; and

$R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each hydrogen.

69. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 61.

70. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 61.